These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30519097)

  • 1. Upregulation of centromere protein F is linked to aggressive prostate cancers.
    Göbel C; Özden C; Schroeder C; Hube-Magg C; Kluth M; Möller-Koop C; Neubauer E; Hinsch A; Jacobsen F; Simon R; Sauter G; Michl U; Pehrke D; Huland H; Graefen M; Schlomm T; Luebke AM
    Cancer Manag Res; 2018; 10():5491-5504. PubMed ID: 30519097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
    Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
    Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
    Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
    Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
    Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
    Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
    Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion.
    Steurer S; Schwemmer L; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Luebke AM; Simon R; Sauter G; Izbicki J; Schroeder C; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Minner S; Meiners J
    Oncotarget; 2019 Dec; 10(67):7096-7111. PubMed ID: 31903168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
    BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
    Luebke AM; Ricken W; Kluth M; Hube-Magg C; Schroeder C; Büscheck F; Möller K; Dum D; Höflmayer D; Weidemann S; Fraune C; Hinsch A; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Minner S; Simon R; Sauter G; Wilczak W; Meiners J
    Int J Cancer; 2020 Jul; 147(2):575-583. PubMed ID: 32150281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
    Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
    Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
    Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.
    Büscheck F; Zub M; Heumann A; Hube-Magg C; Simon R; Lang DS; Höflmayer D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Sauter G; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Clauditz TS; Burandt E; Wilczak W; Steurer S; Minner S
    Tumour Biol; 2019 Jul; 41(7):1010428318824815. PubMed ID: 31296150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
    Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
    Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of CENPF is linked to aggressive features of osteosarcoma.
    Zou PA; Yang ZX; Wang X; Tao ZW
    Oncol Lett; 2021 Sep; 22(3):648. PubMed ID: 34386070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.
    Höflmayer D; Steinhoff A; Hube-Magg C; Kluth M; Simon R; Burandt E; Tsourlakis MC; Minner S; Sauter G; Büscheck F; Wilczak W; Steurer S; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Jacobsen F; Hinsch A; Poos AM; Oswald M; Rippe K; König R; Schroeder C
    Mol Oncol; 2020 Jan; 14(1):129-138. PubMed ID: 31736271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
    Kind S; Büscheck F; Höflmayer D; Hube-Magg C; Kluth M; Tsourlakis MC; Steurer S; Clauditz TS; Luebke AM; Burandt E; Wilczak W; Hinsch A; Dum D; Weidemann S; Fraune C; Beyer B; Steuber T; Huland H; Graefen M; Fisch M; Simon R; Sauter G; Schlomm T; Minner S; Eichenauer T
    World J Urol; 2020 Sep; 38(9):2185-2196. PubMed ID: 31745645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.